Technology
Health
Biotechnology

Paratek Pharmaceuticals

$6.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (0.32%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PRTK and other stocks, options, ETFs, and crypto commission-free!

About

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. Read More The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Employees
104
Headquarters
Boston, Massachusetts
Founded
1996
Market Cap
200.65M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
582.09K
High Today
$6.29
Low Today
$5.95
Open Price
$6.23
Volume
108.64K
52 Week High
$14.15
52 Week Low
$4.50

Collections

Technology
Health
Biotechnology
US
North America

News

Seeking AlphaMar 18

Paratek Pharmaceuticals announces management change

Paratek Pharmaceuticals (PRTK -3.4% ) announces resignation of Douglas Pagán, CFO, effective April 5, 2019 The Company also announces that Sarah Higgins, Paratek’s Vice President and Controller, will serve as the company's Principal Financial Officer and Principal Accounting Officer as the company conducts a search for a new CFO...

57
MarketBeatMar 11

Stock Price, News, & Analysis for Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tet...

7
Seeking AlphaFeb 27

Paratek Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings call. 1 24 Click to enlarge Notes:...

196

Earnings

-$1.01
-$0.89
-$0.76
-$0.64
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.